Ellevest, Inc. United Therapeutics Corp Transaction History

Ellevest, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	BUY	$212.99 - $276.17 $8,732 - $11,322	41 Added 73.21%	97 $21,000
Q4 2022 Feb 03, 2023	BUY	$205.95 - $280.43 $411 - $560	2 Added 3.7%	56 $15,000
Q3 2022 Nov 02, 2022	BUY	$203.3 - $244.17 $3,252 - $3,906	16 Added 42.11%	54 $11,000
Q1 2022 Apr 19, 2022	SELL	$166.16 - $213.96 $3,987 - $5,135	-24 Reduced 38.71%	38 $7,000
Q4 2021 Jan 24, 2022	BUY	$184.32 - $216.08 $368 - $432	2 Added 3.33%	62 $13,000
Q3 2021 Oct 19, 2021	SELL	$179.86 - $214.88 $5,575 - $6,661	-31 Reduced 34.07%	60 $11,000
Q2 2021 Jul 13, 2021	SELL	$170.47 - $211.93 $4,773 - $5,934	-28 Reduced 23.53%	91 $16,000
Q1 2021 May 03, 2021	BUY	$153.94 - $174.85 $7,081 - $8,043	46 Added 63.01%	119 $20,000
Q4 2020 Feb 04, 2021	BUY	$101.87 - $151.79 $7,436 - $11,080	73 New	73 $11,000
Q2 2020 Jul 06, 2020	SELL	$92.74 - $125.82 $2,040 - $2,768	-22 Closed	0 $0
Q1 2020 Apr 13, 2020	BUY	$79.39 - $115.35 $635 - $922	8 Added 57.14%	22 $2,000
Q4 2019 Feb 05, 2020	BUY	$78.31 - $95.34 $1,096 - $1,334	14 New	14 $1,000

679

42.1M

194K

298K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

Stay updated on Ellevest, Inc. with notifications on news.